




Radically Rethinking Breast Cancer Management

September, 2025



Resitu Medical's technology is focused on retrieval of large, intact tissue samples en bloc, during a minimal invasive procedure



1st Product 2025

Replacing

2nd Version 2026

Replacing

Today's Vacuum Assisted Devices


e.g., Mammotome & Becton Dickinson

Open surgery


&

2 steps in 1


Harvest large tissue samples for diagnosis & Removal of the tumor at the same time.



Approaching commercialization






Strategic Scaling & Expansion



Market size calculations

Key Assumptions		
Breast interventions		Biopsies, benign lesion removals, cancer tumors surgeries
# of breast cancer yearly	2.3 million	According to WHO in each country
# of interventions (TOM)	10 million	Prevalence factors to # of breast cancer cases
# suitable for Resitu (SAM)	5 million	Small lesions (< 1.5 cm)
# of products (SOM)	1 million	Reach clinical practice (20% of SAM) after 10 years.
Country entry		According to plan
End user price	€700	
Distributor margin	35%	



Management



Åsa Runnäs
CEO, Partner

20 years in medical device industry with focus on QA/RA, market access, several executive positions



Stefan Sowa
CFO

25 years of executive mgmt. in medical device firms



Elisabeth Liljensten
Chief Clinical Strategy & Middle East, Partner

25 years in medical device industry with clinical focus, several executive positions



Per Egnelöv
CTO

30 years of Class 2&3 medical device development & mfct.



Antonia Claasz
Director of Quality Assurance/Regulatory Affairs

20 plus years experience with medical device industry with focus on QA/RA

Clinical Advisory Board



Prof. Andreas Karakatsanis, MD

Breast Surgery, Uppsala University Hospital



Athanasios Zouzos, MD, PhD

Radiologist, Karolinska University Hospital



Prof. Per Hellman

Professor of Endocrine Surgery
Uppsala University Hospital



Per Hedén
Inventor, founder

Associate Professor of Plastic Surgery at Karolinska Institute

Board of Directors



Håkan Sjunnesson

Chairman of the Board, Founder
Investor, Chairman of several growth companies



Per Hedén
Inventor, founder

Associate Professor of Plastic Surgery at Karolinska Institute



Claes Post

General Partner STOAF III SCITECH, member of several boards



Åsa Runnäs
CEO, Partner

20 years in medical device industry with focus on QA/RA, market access, several executive positions

Series A investment round (expected Q3/Q4 2026)



■ Clinical studies

■ Market expansion & registration

■ Organization & company growth

■ Product development & Regulatory approvals (improved claims, 2nd generation instrument)

■ Other